Edition:
United States

OPKO Health Inc (OPK.OQ)

OPK.OQ on NASDAQ Stock Exchange Global Select Market

2.75USD
20 Feb 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.75
Open
$2.84
Day's High
$2.87
Day's Low
$2.72
Volume
1,751,020
Avg. Vol
1,422,387
52-wk High
$6.39
52-wk Low
$2.34

Latest Key Developments (Source: Significant Developments)

Opko Health, Inc. Announces The Pricing Of Its Offering Of Convertible Senior Notes
Tuesday, 5 Feb 2019 08:30am EST 

Feb 5 (Reuters) - OPKO Health Inc ::OPKO HEALTH, INC. ANNOUNCES THE PRICING OF ITS OFFERING OF CONVERTIBLE SENIOR NOTES.OPKO HEALTH INC - PRICING OF ITS OFFERING OF $200 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025.OPKO HEALTH INC - NOTES WILL PAY INTEREST SEMIANNUALLY IN ARREARS AT A RATE OF 4.50% PER ANNUM, AND WILL MATURE ON FEBRUARY 15, 2025.  Full Article

Opko Health Receives FDA Approval For The Point-Of-Care Sangia PSA Test With The Claros 1 Analyzer
Friday, 1 Feb 2019 08:00am EST 

Feb 1 (Reuters) - OPKO Health Inc ::OPKO HEALTH RECEIVES FDA APPROVAL FOR THE POINT-OF-CARE SANGIA PSA TEST WITH THE CLAROS 1 ANALYZER.OPKO HEALTH INC - PLANS TO EXPAND NUMBER OF ASSAYS ON CLAROS 1 TECHNOLOGY PLATFORM THROUGH FUTURE SUBMISSIONS TO FDA.  Full Article

OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator
Thursday, 31 Jan 2019 09:14pm EST 

Jan 31 (Reuters) - OPKO Health Inc ::OPKO PROVIDES UPDATE ON THE DEVELOPMENT OF OPK-88004, A SELECTIVE ANDROGEN RECEPTOR MODULATOR.OPKO IS CURRENTLY CONDUCTING A PHASE 2 CLINICAL TRIAL THAT EVALUATES EFFECT OF 15MG AND 25MG DOSES OF OPK-88004.OPKO HEALTH- NOTICED TO MEASURE ONE OF STUDY'S PRIMARY ENDPOINTS TRANS-RECTAL ULTRASOUND METHOD PROVED TOO IMPRECISE TO RELIABLY DETERMINE DRUG EFFECT.OPKO PLANS TO SUSPEND CURRENT TRIAL BUT CONTINUE TO ANALYZE DATA RELATING TO OTHER PRIMARY ENDPOINT.OPKO IS PLANNING ADDITIONAL EXPLORATORY PHASE 2 CLINICAL STUDIES TO ASSESS FEASIBILITY OF OPK-88004 IN OTHER INDICATIONS.OPKO HEALTH-MOST OF LABORATORY CHANGES WERE CONSISTENT WITH OPK-88004, INCREASES IN LIVER ENZYMES WERE OBSERVED IN SEVERAL MEN AT THESE HIGHER DOSES.  Full Article

Opko Health Q3 Loss Per Share $0.05
Friday, 9 Nov 2018 04:01pm EST 

OPKO Health Inc ::OPKO HEALTH REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.05.Q3 REVENUE $249.8 MILLION VERSUS I/B/E/S VIEW $264 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.08 -- THOMSON REUTERS I/B/E/S.  Full Article

Phillip Frost Issues Statement Regarding SEC Lawsuit
Friday, 14 Sep 2018 04:17pm EDT 

Sept 14 (Reuters) - Phillip Frost::PHILLIP FROST ISSUES STATEMENT REGARDING SEC LAWSUIT.PHILLIP FROST - INVESTED IN 2 OF ENTITIES IDENTIFIED IN SEC COMPLAINT; REMAIN "SIGNIFICANT LONG-TERM" SHAREHOLDER IN BOTH COS.PHILLIP FROST SAYS "STUNNED BY SEC'S LAWSUIT AND DENY ALLEGATIONS IT CONTAINS AGAINST ME".  Full Article

Opko Comments On SEC Complaint
Friday, 7 Sep 2018 08:11pm EDT 

Sept 7 (Reuters) - OPKO Health Inc ::OPKO COMMENTS ON SEC COMPLAINT.SAYS "SEC FAILED TO PROVIDE NOTICE OF ITS INTENT TO SUE PRIOR TO FILING COMPLAINT".SAYS SEC COMPLAINT "CONTAINS SERIOUS FACTUAL INACCURACIES".  Full Article

OPKO Health Q2 Loss Per Share $0.01
Tuesday, 7 Aug 2018 04:05pm EDT 

Aug 7 (Reuters) - OPKO Health Inc ::OPKO HEALTH REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.01.Q2 REVENUE $263.7 MILLION VERSUS I/B/E/S VIEW $261.7 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.07 -- THOMSON REUTERS I/B/E/S.  Full Article

OPKO Health Inc Says Intends To Remain On Tel Aviv Stock Exchange
Friday, 27 Apr 2018 04:30pm EDT 

April 27 (Reuters) - OPKO Health Inc ::OPKO HEALTH INC - INTENDS TO REMAIN ON TEL AVIV STOCK EXCHANGE AND WITHDRAW ITS REQUEST TO VOLUNTARILY DELIST ITS COMMON STOCK FROM TASE.OPKO HEALTH TO REMAIN ON TEL AVIV STOCK EXCHANGE.OPKO HEALTH - HAVE SPOKEN WITH CO'S ISRAEL-BASED INVESTORS; THEY EXPRESSED DESIRE CO CONTINUE PRESENCE ON TASE AND URGED CO TO RECONSIDER DECISION.  Full Article

Opko Health qtrly loss per share $0.08‍​
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Opko Health Inc ::Opko Health reports 2017 third quarter highlights and financial results.Q3 revenue $263.5 million versus I/B/E/S view $319.4 million.Opko Health Inc qtrly loss per share $0.08‍​.  Full Article

OPKO Health submits premarket approval application with FDA for PSA test
Tuesday, 7 Nov 2017 08:00am EST 

Nov 7 (Reuters) - OPKO Health Inc :OPKO Health submits premarket approval application with FDA for a point-of-care PSA test with the Claros 1 platform.OPKO Health Inc - ‍filing contains clinical data from company's 864-patient total psa clinical study​.OPKO Health Inc - ‍OPKO expects to initiate clinical validation studies and to file a 510(k) application for a Claros 1 testosterone test in 2018​.OPKO Health - working to add additional tests for vitamin D, infectious diseases, cardiology, women's health, companion diagnostics to Claros 1 menu​.  Full Article

UPDATE 1-IFR Americas ECM Pipeline

NEW YORK, Feb 5 (IFR) - PRICED Invesco Mortgage Capital (US, mortgage REIT) – $220m Block. 14m shares (100% prim) at $15.73 versus $15.73 fixed-price marketing and $16.30 last sale. MS, CITI, CS. Marcus Corporation (US, movie theaters) – $60.4m Block. 1.5m shares (100% sec) at $40.25 versus $40.25-$40.72 marketing and $40.72 last sale. GS. OPKO Health (US, pharmaceutical) – $200m 6y cvt priced at 4.25%, up 20%. JEFF. CALENDAR Week of Feb 4: Wealthbridge Acquisition (US, SPAC) – $50m IPO. 5m unit